跳至主要内容
临床试验/NL-OMON54983
NL-OMON54983已完成4 期

Comparison of DTM SCS Therapy Combined with standard pain treatment to standard pain treatment alone in the Treatment of Intractable Back Pain Subjects without previous history of Lumbar Spine Surgery - DTM-INT 2020PM2

SGX International LLC (SGX Health Europe)0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • A subject must MEET ALL of the following inclusion criteria:
  • 1. Be a candidate for SCS system (trial and implant)
  • 2. Have been diagnosed with chronic, refractory axial low back pain with or
  • without lower limb pain, with a neuropathic component as assessed by the
  • investigator, 6 months refractory to conventional therapy and are not eligible
  • for spine surgery (e.g., lumbar fusion, discectomy, laminectomy, laminotomy) at
  • the time of enrollment.
  • 3. Has an average back pain intensity >= 6.0 cm on the 10.0 cm Visual Analog
  • Scale (VAS) at the time of enrollment
  • 4. Be willing and capable of giving written informed consent to participate in
  • this clinical study based on voluntary agreement after a thorough explanation
  • of the subject*s participation has been provided.
  • 5. Be willing and capable of subjective evaluation, read and understand written
  • questionnaires, and read, understand and sign the written inform consent.
  • 6. Be 18 years of age or older at the time of enrollment
  • 7. Be on a stable pain medication regimen, as determined by the study
  • investigator, for at least 30 days prior to enrolling in this study
  • 8. Be willing and able to comply with study-related requirements, procedures,

排除标准

  • A subject must NOT MEET ANY of the following exclusion criteria:
  • 1. Had previous lumbar spinal surgery (e.g., lumbar fusion, discectomy,
  • laminectomy, laminotomy)
  • 2. Has a medical, anatomical, and/or psychosocial condition that is
  • contraindicated for commercially available IntellisTM SCS systems as determined
  • by the Investigator
  • 3. Has a diagnosed back condition with inflammatory causes of back pain (e.g.,
  • onset of severe pain with activity), serious spinal pathology and/or
  • neurological disorders as determined by the investigator
  • 4. Be concurrently participating in another clinical study
  • 5. Has an existing active implanted device such as a pacemaker, another SCS
  • unit, peripheral nerve stimulator, and/or drug delivery pump, etc.
  • 6. Has a pain in other area(s) and/or medical condition requiring the regular
  • use of significant pain medications that could interfere with accurate pain
  • reporting, and/or confound evaluation of study endpoints, as determined by the
  • Investigator
  • 7. Has mechanical spine instability as determined by the Investigator
  • 8. Has undergone, within 30 days prior to enrollment, an interventional
  • procedure to treat back and/or leg pain, which is providing significant pain
  • 9. Has unresolved major issues of secondary gain (e.g., social, financial,
  • legal), as determined by the investigator
  • 10. Be involved in an injury claim under current litigation or has a pending or
  • has a pending or approved worker*s compensation claim
  • 11. Be pregnant (determined by urine testing unless female subject is
  • surgically sterile or post-menopausal. If female, sexually active, and
  • childbearing age, subject must be willing to use a reliable form of birth

研究者

发起方
SGX International LLC (SGX Health Europe)

相似试验